United States Fatty Liver Disease Drug Market Report 2017

December 2017 | 101 pages | ID: UFAB3C3B86EEN
QYResearch

Abstracts

In this report, the United States Fatty Liver Disease Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Fatty Liver Disease Drug in these regions, from 2012 to 2022 (forecast).

United States Fatty Liver Disease Drug market competition by top manufacturers/players, with Fatty Liver Disease Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Pfizer
• Conatus Pharmaceuticals
• Novartis
• Intercept Pharmaceuticals
• Allergan
• Immuron
• Takeda
• Gilead Sciences
• Genfit

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• By Type 1
• Granulocyte Colony Stimulating Factor Drug
• Opioid Antagonist Drug
• Pentoxifylline Drug
• Glucocorticoid Drug
• By Type 2
• Alcoholic Fatty Liver
• Non Alcoholic Fatty Liver

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospital
• Medical Center

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Fatty Liver Disease Drug Market Report 2017

1 FATTY LIVER DISEASE DRUG OVERVIEW

1.1 Product Overview and Scope of Fatty Liver Disease Drug
1.2 Classification of Fatty Liver Disease Drug by Product Category
  1.2.1 United States Fatty Liver Disease Drug Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Fatty Liver Disease Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Granulocyte Colony Stimulating Factor Drug
  1.2.4 Opioid Antagonist Drug
  1.2.5 Pentoxifylline Drug
  1.2.6 Glucocorticoid Drug
1.3 United States Fatty Liver Disease Drug Market by Application/End Users
  1.3.1 United States Fatty Liver Disease Drug Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospital
  1.3.3 Medical Center
1.4 United States Fatty Liver Disease Drug Market by Region
  1.4.1 United States Fatty Liver Disease Drug Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Fatty Liver Disease Drug Status and Prospect (2012-2022)
  1.4.3 Southwest Fatty Liver Disease Drug Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Fatty Liver Disease Drug Status and Prospect (2012-2022)
  1.4.5 New England Fatty Liver Disease Drug Status and Prospect (2012-2022)
  1.4.6 The South Fatty Liver Disease Drug Status and Prospect (2012-2022)
  1.4.7 The Midwest Fatty Liver Disease Drug Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Fatty Liver Disease Drug (2012-2022)
  1.5.1 United States Fatty Liver Disease Drug Sales and Growth Rate (2012-2022)
  1.5.2 United States Fatty Liver Disease Drug Revenue and Growth Rate (2012-2022)

2 UNITED STATES FATTY LIVER DISEASE DRUG MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Fatty Liver Disease Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Fatty Liver Disease Drug Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Fatty Liver Disease Drug Average Price by Players/Suppliers (2012-2017)
2.4 United States Fatty Liver Disease Drug Market Competitive Situation and Trends
  2.4.1 United States Fatty Liver Disease Drug Market Concentration Rate
  2.4.2 United States Fatty Liver Disease Drug Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Fatty Liver Disease Drug Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES FATTY LIVER DISEASE DRUG SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Fatty Liver Disease Drug Sales and Market Share by Region (2012-2017)
3.2 United States Fatty Liver Disease Drug Revenue and Market Share by Region (2012-2017)
3.3 United States Fatty Liver Disease Drug Price by Region (2012-2017)

4 UNITED STATES FATTY LIVER DISEASE DRUG SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Fatty Liver Disease Drug Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Fatty Liver Disease Drug Revenue and Market Share by Type (2012-2017)
4.3 United States Fatty Liver Disease Drug Price by Type (2012-2017)
4.4 United States Fatty Liver Disease Drug Sales Growth Rate by Type (2012-2017)

5 UNITED STATES FATTY LIVER DISEASE DRUG SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Fatty Liver Disease Drug Sales and Market Share by Application (2012-2017)
5.2 United States Fatty Liver Disease Drug Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES FATTY LIVER DISEASE DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Pfizer
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Fatty Liver Disease Drug Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Pfizer Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Conatus Pharmaceuticals
  6.2.2 Fatty Liver Disease Drug Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Conatus Pharmaceuticals Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Novartis
  6.3.2 Fatty Liver Disease Drug Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Novartis Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Intercept Pharmaceuticals
  6.4.2 Fatty Liver Disease Drug Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Intercept Pharmaceuticals Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Allergan
  6.5.2 Fatty Liver Disease Drug Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Allergan Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Immuron
  6.6.2 Fatty Liver Disease Drug Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Immuron Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Takeda
  6.7.2 Fatty Liver Disease Drug Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Takeda Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Gilead Sciences
  6.8.2 Fatty Liver Disease Drug Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Gilead Sciences Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Genfit
  6.9.2 Fatty Liver Disease Drug Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Genfit Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview

7 FATTY LIVER DISEASE DRUG MANUFACTURING COST ANALYSIS

7.1 Fatty Liver Disease Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Fatty Liver Disease Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Fatty Liver Disease Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Fatty Liver Disease Drug Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES FATTY LIVER DISEASE DRUG MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Fatty Liver Disease Drug Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Fatty Liver Disease Drug Sales Volume Forecast by Type (2017-2022)
11.3 United States Fatty Liver Disease Drug Sales Volume Forecast by Application (2017-2022)
11.4 United States Fatty Liver Disease Drug Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Fatty Liver Disease Drug
Figure United States Fatty Liver Disease Drug Market Size (K Pcs) by Type (2012-2022)
Figure United States Fatty Liver Disease Drug Sales Volume Market Share by Type (Product Category) in 2016
Figure Granulocyte Colony Stimulating Factor Drug Product Picture
Figure Opioid Antagonist Drug Product Picture
Figure Pentoxifylline Drug Product Picture
Figure Glucocorticoid Drug Product Picture
Figure United States Fatty Liver Disease Drug Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Fatty Liver Disease Drug by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Medical Center Examples
Table Key Downstream Customer in Medical Center
Figure United States Fatty Liver Disease Drug Market Size (Million USD) by Region (2012-2022)
Figure The West Fatty Liver Disease Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Fatty Liver Disease Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Fatty Liver Disease Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Fatty Liver Disease Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Fatty Liver Disease Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Fatty Liver Disease Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Fatty Liver Disease Drug Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Fatty Liver Disease Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Fatty Liver Disease Drug Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Fatty Liver Disease Drug Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Fatty Liver Disease Drug Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Fatty Liver Disease Drug Sales Share by Players/Suppliers
Figure 2017 United States Fatty Liver Disease Drug Sales Share by Players/Suppliers
Figure United States Fatty Liver Disease Drug Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Fatty Liver Disease Drug Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Fatty Liver Disease Drug Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Fatty Liver Disease Drug Revenue Share by Players/Suppliers
Figure 2017 United States Fatty Liver Disease Drug Revenue Share by Players/Suppliers
Table United States Market Fatty Liver Disease Drug Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Fatty Liver Disease Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Fatty Liver Disease Drug Market Share of Top 3 Players/Suppliers
Figure United States Fatty Liver Disease Drug Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Fatty Liver Disease Drug Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Fatty Liver Disease Drug Product Category
Table United States Fatty Liver Disease Drug Sales (K Pcs) by Region (2012-2017)
Table United States Fatty Liver Disease Drug Sales Share by Region (2012-2017)
Figure United States Fatty Liver Disease Drug Sales Share by Region (2012-2017)
Figure United States Fatty Liver Disease Drug Sales Market Share by Region in 2016
Table United States Fatty Liver Disease Drug Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Fatty Liver Disease Drug Revenue Share by Region (2012-2017)
Figure United States Fatty Liver Disease Drug Revenue Market Share by Region (2012-2017)
Figure United States Fatty Liver Disease Drug Revenue Market Share by Region in 2016
Table United States Fatty Liver Disease Drug Price (USD/Pcs) by Region (2012-2017)
Table United States Fatty Liver Disease Drug Sales (K Pcs) by Type (2012-2017)
Table United States Fatty Liver Disease Drug Sales Share by Type (2012-2017)
Figure United States Fatty Liver Disease Drug Sales Share by Type (2012-2017)
Figure United States Fatty Liver Disease Drug Sales Market Share by Type in 2016
Table United States Fatty Liver Disease Drug Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Fatty Liver Disease Drug Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Fatty Liver Disease Drug by Type (2012-2017)
Figure Revenue Market Share of Fatty Liver Disease Drug by Type in 2016
Table United States Fatty Liver Disease Drug Price (USD/Pcs) by Types (2012-2017)
Figure United States Fatty Liver Disease Drug Sales Growth Rate by Type (2012-2017)
Table United States Fatty Liver Disease Drug Sales (K Pcs) by Application (2012-2017)
Table United States Fatty Liver Disease Drug Sales Market Share by Application (2012-2017)
Figure United States Fatty Liver Disease Drug Sales Market Share by Application (2012-2017)
Figure United States Fatty Liver Disease Drug Sales Market Share by Application in 2016
Table United States Fatty Liver Disease Drug Sales Growth Rate by Application (2012-2017)
Figure United States Fatty Liver Disease Drug Sales Growth Rate by Application (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Fatty Liver Disease Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Pfizer Fatty Liver Disease Drug Sales Growth Rate (2012-2017)
Figure Pfizer Fatty Liver Disease Drug Sales Market Share in United States (2012-2017)
Figure Pfizer Fatty Liver Disease Drug Revenue Market Share in United States (2012-2017)
Table Conatus Pharmaceuticals Basic Information List
Table Conatus Pharmaceuticals Fatty Liver Disease Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Conatus Pharmaceuticals Fatty Liver Disease Drug Sales Growth Rate (2012-2017)
Figure Conatus Pharmaceuticals Fatty Liver Disease Drug Sales Market Share in United States (2012-2017)
Figure Conatus Pharmaceuticals Fatty Liver Disease Drug Revenue Market Share in United States (2012-2017)
Table Novartis Basic Information List
Table Novartis Fatty Liver Disease Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Novartis Fatty Liver Disease Drug Sales Growth Rate (2012-2017)
Figure Novartis Fatty Liver Disease Drug Sales Market Share in United States (2012-2017)
Figure Novartis Fatty Liver Disease Drug Revenue Market Share in United States (2012-2017)
Table Intercept Pharmaceuticals Basic Information List
Table Intercept Pharmaceuticals Fatty Liver Disease Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Intercept Pharmaceuticals Fatty Liver Disease Drug Sales Growth Rate (2012-2017)
Figure Intercept Pharmaceuticals Fatty Liver Disease Drug Sales Market Share in United States (2012-2017)
Figure Intercept Pharmaceuticals Fatty Liver Disease Drug Revenue Market Share in United States (2012-2017)
Table Allergan Basic Information List
Table Allergan Fatty Liver Disease Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Allergan Fatty Liver Disease Drug Sales Growth Rate (2012-2017)
Figure Allergan Fatty Liver Disease Drug Sales Market Share in United States (2012-2017)
Figure Allergan Fatty Liver Disease Drug Revenue Market Share in United States (2012-2017)
Table Immuron Basic Information List
Table Immuron Fatty Liver Disease Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Immuron Fatty Liver Disease Drug Sales Growth Rate (2012-2017)
Figure Immuron Fatty Liver Disease Drug Sales Market Share in United States (2012-2017)
Figure Immuron Fatty Liver Disease Drug Revenue Market Share in United States (2012-2017)
Table Takeda Basic Information List
Table Takeda Fatty Liver Disease Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Takeda Fatty Liver Disease Drug Sales Growth Rate (2012-2017)
Figure Takeda Fatty Liver Disease Drug Sales Market Share in United States (2012-2017)
Figure Takeda Fatty Liver Disease Drug Revenue Market Share in United States (2012-2017)
Table Gilead Sciences Basic Information List
Table Gilead Sciences Fatty Liver Disease Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Gilead Sciences Fatty Liver Disease Drug Sales Growth Rate (2012-2017)
Figure Gilead Sciences Fatty Liver Disease Drug Sales Market Share in United States (2012-2017)
Figure Gilead Sciences Fatty Liver Disease Drug Revenue Market Share in United States (2012-2017)
Table Genfit Basic Information List
Table Genfit Fatty Liver Disease Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Genfit Fatty Liver Disease Drug Sales Growth Rate (2012-2017)
Figure Genfit Fatty Liver Disease Drug Sales Market Share in United States (2012-2017)
Figure Genfit Fatty Liver Disease Drug Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Fatty Liver Disease Drug
Figure Manufacturing Process Analysis of Fatty Liver Disease Drug
Figure Fatty Liver Disease Drug Industrial Chain Analysis
Table Raw Materials Sources of Fatty Liver Disease Drug Major Players/Suppliers in 2016
Table Major Buyers of Fatty Liver Disease Drug
Table Distributors/Traders List
Figure United States Fatty Liver Disease Drug Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Fatty Liver Disease Drug Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Fatty Liver Disease Drug Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Fatty Liver Disease Drug Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Fatty Liver Disease Drug Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Fatty Liver Disease Drug Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Fatty Liver Disease Drug Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Fatty Liver Disease Drug Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Fatty Liver Disease Drug Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Fatty Liver Disease Drug Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Fatty Liver Disease Drug Sales Volume Share Forecast by Region (2017-2022)
Figure United States Fatty Liver Disease Drug Sales Volume Share Forecast by Region (2017-2022)
Figure United States Fatty Liver Disease Drug Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources